| 2014-07-03 |
1 |
|
January 8, 2008, United States
Patent No. RE40,000 (“the ’000 patent”), entitled “Method of Treatment…action for infringement of United States Patent No. RE40,000 relating
to the use of carvedilol in decreasing…manufacture drug products covered by United States Patent No. RE40,000 for sale and use
throughout the United States…original ’069 patent, the ’000 patent expires on June 7, 2015. The ’000 patent is the only patent
currently…the ’069 patent. Until it was replaced by the reissued ’000 patent, the
’069 patent had a patent term until |
External link to document |
| 2016-03-02 |
125 |
Memorandum and Order |
to before the asserted patent, U.S. Patent No. RE40,000 E (the “'000 patent”), issued in
January 2008…acts of inducement
occurred before there existed a patent to be infringed.”’ (D.I. 115 at 1-2 (quoting Nal…Teva’s validity
challenge against the '000 patent)); see also Fed. R. Civ. P. 26(b)(1).
2 The…analyses regarding Teva’s manufacturing decisions and patent enforcement relating to
carvedilol), it seems even…2014
25 April 2018
1:14-cv-00878
830 Patent
Plaintiff
District Court, D. Delaware |
External link to document |
| 2016-07-20 |
191 |
Report and Recommendations |
#x27;069 patent reissued as United
States Patent No. RE40,000 (the '"000 patent"), entitled….S. Patent No. 5,760,069 (the '"069 patent"). (Id. at ,-r 35) The '069 patent is entitled…x27;000 patent covered the post-MILVD indication, (SAC at if 40). Patent
owners list patents along with…must identify specific patent information with respect to which a claim of
patent infringement could &…use or related
indication and related patent claim of the patent being submitted" and (2) provide |
External link to document |
| 2016-09-19 |
201 |
Notice of Service |
., M.P.H. Regarding Infringement of U.S. Patent No. RE40,000 by Teva Pharmaceuticals USA, Inc.; (3) Expert…2014
25 April 2018
1:14-cv-00878
830 Patent
Plaintiff
District Court, D. Delaware |
External link to document |
| 2017-01-27 |
248 |
|
1) Claims 1-3 and 6-9 of U.S. Patent No. RE40,000 are invalid under 35 U.S.C. § 102
…of claims.
2) Claim 4 of U.S. Patent No. RE40,000 is invalid as obvious under 35 U.S.C. § 103… “Olsen”).
3) Claim 4 of U.S. Patent No. RE40,000 is invalid as obvious under 35 U.S.C. § 103…infringement of the asserted claims of U.S. Patent No.
RE40,000 because Plaintiffs have failed to…infringement of the asserted claims of U.S. Patent No.
RE40,000 during the “Skinny Label” period. |
External link to document |
